Weikang Bio-tech 8-K Entry into a Material Definitive Agreement

Expedition Leasing, Inc.

and Sinary Bio-Technology Holdings Group, Inc. and Subsidiary

Pro forma Combined Balance Sheet

As of September 30, 2007

(unaudited)

	Expedition						Pro forma			Pro forma
	Leasing (1)			Sinary (2)			Adjustments			Combined
	(historical)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	1,979		$	101,180		$			$	103,159
Accounts receivable, net					7,207						7,207
Other receivables					16,004						16,004
Due from shareholder					2,737,408						2,737,408
Due from related parties					4,089						4,089
Inventory					324,216						324,216
TOTAL CURRENT ASSETS		1,979			3,190,104			-			3,192,083
ADVANCES FOR CONSTRUCTION AND EQUIPMENT					191,430						191,430
PROPERTY AND EQUIPMENT, NET					4,109,798						4,109,798
CONSTRUCTION IN PROGRESS					2,669						2,669
INTANGIBLE ASSETS					252,807						252,807
TOTAL ASSETS	$	1,979		$	7,746,808		$	-		$	7,748,787
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable	$	46,812		$	82,318		$	(46,812)	(a)	$	82,318
Other payables					7,664,490						7,664,490
Accrued expenses		24,350						(24,350)	(a)		-
Due to related party		60,000						(60,000)	(a)		-
Due to shareholder					650,000	(d)					650,000
TOTAL CURRENT LIABILITIES		131,162			8,396,808			(131,162	)		8,396,808
STOCKHOLDERS' EQUITY
Common Stock		252						-	(b)		252
Additional paid in capital		119,489						(117,762)	(a)		1,727
Subscription Receivable											-
Statutory reserve											-
Retained earnings (accumulated deficit)		(248,924	)		(650,000)	(d)		248,924	(a)		(650,000	)
TOTAL STOCKHOLDERS' EQUITY		(129,183	)		(650,000	)		131,162			(648,021	)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	1,979		$	7,746,808		$	-		$	7,748,787

(1) Source: unaudited financial statements of Expedition Leasing, Inc. as of September 30, 2007 as filed in Quarterly Report on Form 10QSB filed with the SEC on November 14, 2007.

(2) Source: unaudited financial statements of Heilongjiang Weikang Bio-Technology Group Co., Ltd. ("Weikang") (a wholly owned subsidiary of Sinary) as of September 30, 2007 included in this 8-K, consolidated with Sinary on a pro forma basis. Sinary acquired Weikang on October 25, 2006 for $7.6 million by assumption of debt.

(a) Elimination of accumulated deficit, capital accounts as a result of recapitalization, and reflection of payment of all liabilities of EXDG prior to closing.

(b) After cancellation of 24,725,200 shares by the old shareholders of Expedition and issuance of 24,725,200 shares to the shareholder of Sinary 

See accompanying notes to pro forma combined financial statements

F-1

Expedition Leasing, Inc.

and Sinary Bio-Technology Holdings Group, Inc. and Subsidiary

Pro forma Combined Statement of Operations

For the Nine Months Ended September 30, 2007

(unaudited)

	Expedition						Pro forma		Pro forma
	Leasing (1)			Sinary (2)			Adjustments		Combined
	(historical)
Net Revenue	$	9,287		$	2,935,010		$		$	2,944,297
Cost of Revenue		-			1,474,004					1,474,004
Gross Profit		9,287			1,461,006			-		1,470,293
Operating expenses:
Selling expenses		-			7,651					7,651
General and administrative expenses		56,585			230,816					287,401
Total operating expenses		56,585			238,467			-		295,052
Income (loss) from operations		(47,298	)		1,222,539			-		1,175,241
Non-operating expenses:
Interest income expense		(5,043	)							(5,043	)
Finance expenses					(128	)				(128	)
Other expenses					(1,721	)				(1,721	)
Total non-operating expenses		(5,043	)		(1,849	)		-		(6,892	)
Income (loss) before income tax		(52,341	)		1,220,690			-		1,168,349
Net income (loss)	$	(52,341	)	$	1,220,690		$	-	$	1,168,349
Earnings per share	$	(0.00	)						$	0.05
Weighted average shares outstanding		25,229,800								25,229,800

(1) Source: unaudited financial statements of Expedition Leasing, Inc. as of September 30, 2007 as filed in Quarterly Report on Form 10QSB filed with the SEC on November 14, 2007.

(2) Source: unaudited financial statements of Heilongjiang Weikang Bio-Technology Group Co., Ltd. ("Weikang") (a wholly owned subsidiary of Sinary) as of September 30, 2007 included in this Form 8-K, consolidated with Sinary on a pro forma basis. Sinary acquired Weikang on October 25, 2007 for $7.6 million by assumption of debt.

See accompanying notes to pro forma combined financial statements

F-2

Expedition Leasing, Inc.

and Sinary Bio-Technology Holdings Group, Inc. and Subsidiary

Pro forma Combined Statement of Operations

For the Year Ended December 31, 2006

(unaudited)

	Expedition						Pro forma		Pro forma
	Leasing (1)			Sinary (2)			Adjustments		Combined
	(historical)
Net Revenue	$	9,600		$	2,487,148		$		$	2,496,748
Cost of Revenue		-			1,201,858					1,201,858
Gross Profit		9,600			1,285,290			-		1,294,890
Operating expenses:
Selling expenses		-			13,434					13,434
General and administrative expenses		109,790			210,562					320,352
Total operating expenses		109,790			223,996			-		333,786
Income (loss) from operations		(100,190	)		1,061,294			-		961,104
Non-operating income (expenses):
Other expense		-			(4,458	)				(4,458	)
Interest income		3,573			3,556					7,129
Interest expense		(8,000	)		-					(8,000	)
Total non-operating expenses		(4,427	)		(902	)		-		(5,329	)
Income (loss) before income tax		(104,617	)		1,060,392			-		955,775
Net income (loss)	$	(104,617	)	$	1,060,392		$	-	$	955,775
Earnings per share	$	(0.00	)						$	0.04
Weighted average shares outstanding		25,229,800								25,229,800

(1) Source: audited financial statements of Expedition Leasing, Inc. for the year ended December 31, 2006 as filed in Annual Report on Form 10-KSB filed with the SEC on April 2, 2007.

(2) Source: audited financial statements of Heilongjiang Weikang Bio-Technology Group Co., Ltd. ("Weikang") (a wholly owned subsidiary of Sinary) for the year ended December 31, 2006 included in Form 8-K, consolidated with Sinary on a pro forma basis.

See accompanying notes to pro forma combined financial statements

F-3

Expedition Leasing, Inc. and

Sinary Bio-Technology Holdings Group, Inc. and subsidiary

Notes to Pro forma Combined Financial Statements

NOTE 1 - BASIS OF PRESENTATION

The accompanying pro forma combined balance sheet presents the accounts of Expedition Leasing, Inc. ("Expedition Leasing") and Sinary Bio-Technology Holdings Group, Inc. and subsidiary (collectively “Sinary”) as if both the acquisition of subsidiary by Sinary and the acquisition of Sinary by Expedition Leasing occurred on September 30, 2007. The accompanying pro forma combined statements of operations present the accounts of Expedition Leasing and Sinary for the year ended December 31, 2006 and the nine months ended September 30, 2007 as if both the acquisition of subsidiary by Sinary and the acquisition of Sinary by Expedition Leasing occurred on January 1, 2006 and January 1, 2007 for income statement purposes, and on September 30, 2007 for balance sheet purposes. For accounting purposes, the acquisition of Sinary by Expedition Leasing is being accounted for as a recapitalization of Sinary.

The following adjustments would be required if the acquisition occurred as indicated above:

a. Recapitalization of Sinary to account for issuance of an aggregate of 24,725,200 shares of Expedition Leasing to the shareholders of Sinary, the total issued and outstanding shares after the reverse merger were 25,229,800;

b. Cancellation of 24,725,200 shares of Expedition Leasing common stock owned by major shareholder, president of Expedition Leasing and public float as part of the transaction;

c. Elimination of accumulated deficit, capital accounts as a result of recapitalization, and reflection of payment of all liabilities of Expedition Leasing prior to closing.

d. The payment of $650,000 for the cost of the shell is not reflected in the pro forma statement of operations as it is a non recurring expense. This amount however is reflected in the pro forma balance sheet.

e.  The pro forma consolidation of Weikang with Sinary is based on a preliminary allocation of purchase price.

f.  Sinary has no assets or operations other than the investment in Weikang of RMB 57 million by assumption of debt.

F-4